vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and TXO Partners, L.P. (TXO). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $103.7M, roughly 1.9× TXO Partners, L.P.). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs -27.2%, a 39.3% gap on every dollar of revenue. On growth, TXO Partners, L.P. posted the faster year-over-year revenue change (14.5% vs 11.1%). Over the past eight quarters, TXO Partners, L.P.'s revenue compounded faster (23.1% CAGR vs 17.3%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

TXO Partners, L.P. is a U.S.-based energy sector master limited partnership. It acquires, develops and manages oil and natural gas assets across key North American production basins, with operations covering upstream exploration, production and midstream transportation, serving industrial, utility and wholesale energy clients.

CORT vs TXO — Head-to-Head

Bigger by revenue
CORT
CORT
1.9× larger
CORT
$202.1M
$103.7M
TXO
Growing faster (revenue YoY)
TXO
TXO
+3.3% gap
TXO
14.5%
11.1%
CORT
Higher net margin
CORT
CORT
39.3% more per $
CORT
12.0%
-27.2%
TXO
Faster 2-yr revenue CAGR
TXO
TXO
Annualised
TXO
23.1%
17.3%
CORT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CORT
CORT
TXO
TXO
Revenue
$202.1M
$103.7M
Net Profit
$24.3M
$-28.3M
Gross Margin
98.7%
Operating Margin
2.2%
-26.1%
Net Margin
12.0%
-27.2%
Revenue YoY
11.1%
14.5%
Net Profit YoY
-21.0%
-376.5%
EPS (diluted)
$0.20
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
TXO
TXO
Q4 25
$202.1M
$103.7M
Q3 25
$207.6M
$90.6M
Q2 25
$194.4M
$75.0M
Q1 25
$157.2M
$93.8M
Q4 24
$181.9M
$90.6M
Q3 24
$182.5M
$69.3M
Q2 24
$163.8M
$57.0M
Q1 24
$146.8M
$68.5M
Net Profit
CORT
CORT
TXO
TXO
Q4 25
$24.3M
$-28.3M
Q3 25
$19.7M
$4.4M
Q2 25
$35.1M
$-135.0K
Q1 25
$20.5M
$2.4M
Q4 24
$30.7M
$10.2M
Q3 24
$47.2M
$203.0K
Q2 24
$35.5M
$2.8M
Q1 24
$27.8M
$10.3M
Gross Margin
CORT
CORT
TXO
TXO
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Q1 24
98.3%
Operating Margin
CORT
CORT
TXO
TXO
Q4 25
2.2%
-26.1%
Q3 25
4.9%
4.2%
Q2 25
13.7%
-5.0%
Q1 25
2.2%
-3.8%
Q4 24
13.9%
6.1%
Q3 24
25.5%
-7.2%
Q2 24
21.7%
-17.7%
Q1 24
20.1%
3.9%
Net Margin
CORT
CORT
TXO
TXO
Q4 25
12.0%
-27.2%
Q3 25
9.5%
4.8%
Q2 25
18.1%
-0.2%
Q1 25
13.1%
2.6%
Q4 24
16.9%
11.3%
Q3 24
25.9%
0.3%
Q2 24
21.7%
4.9%
Q1 24
18.9%
15.0%
EPS (diluted)
CORT
CORT
TXO
TXO
Q4 25
$0.20
$-0.57
Q3 25
$0.16
$0.08
Q2 25
$0.29
$0.00
Q1 25
$0.17
$0.06
Q4 24
$0.25
$0.22
Q3 24
$0.41
$0.01
Q2 24
$0.32
$0.09
Q1 24
$0.25
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
TXO
TXO
Cash + ST InvestmentsLiquidity on hand
$372.2M
$9.4M
Total DebtLower is stronger
$291.1M
Stockholders' EquityBook value
$647.8M
Total Assets
$836.7M
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
TXO
TXO
Q4 25
$372.2M
$9.4M
Q3 25
$421.7M
$5.3M
Q2 25
$342.2M
$8.0M
Q1 25
$322.8M
$10.8M
Q4 24
$383.3M
$7.3M
Q3 24
$380.3M
$3.8M
Q2 24
$473.2M
$76.0M
Q1 24
$410.8M
$4.6M
Total Debt
CORT
CORT
TXO
TXO
Q4 25
$291.1M
Q3 25
$271.1M
Q2 25
$19.1M
Q1 25
$162.1M
Q4 24
$157.1M
Q3 24
$155.1M
Q2 24
$7.1M
Q1 24
$26.1M
Stockholders' Equity
CORT
CORT
TXO
TXO
Q4 25
$647.8M
Q3 25
$631.9M
Q2 25
$635.8M
Q1 25
$683.3M
Q4 24
$679.6M
Q3 24
$638.8M
Q2 24
$596.2M
Q1 24
$547.9M
Total Assets
CORT
CORT
TXO
TXO
Q4 25
$836.7M
$1.4B
Q3 25
$823.6M
$1.4B
Q2 25
$801.7M
$1.0B
Q1 25
$846.5M
$1.0B
Q4 24
$840.6M
$1.0B
Q3 24
$784.3M
$1.0B
Q2 24
$714.6M
$774.5M
Q1 24
$655.9M
$688.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
TXO
TXO
Operating Cash FlowLast quarter
$38.4M
$32.5M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
TXO
TXO
Q4 25
$38.4M
$32.5M
Q3 25
$54.5M
$28.3M
Q2 25
$43.9M
$26.9M
Q1 25
$5.1M
$30.6M
Q4 24
$59.3M
$40.5M
Q3 24
$73.8M
$20.7M
Q2 24
$41.2M
$22.9M
Q1 24
$23.8M
$25.2M
Free Cash Flow
CORT
CORT
TXO
TXO
Q4 25
$38.4M
Q3 25
Q2 25
$43.9M
Q1 25
$5.0M
Q4 24
$59.2M
Q3 24
$72.2M
Q2 24
$40.8M
Q1 24
FCF Margin
CORT
CORT
TXO
TXO
Q4 25
19.0%
Q3 25
Q2 25
22.6%
Q1 25
3.2%
Q4 24
32.5%
Q3 24
39.5%
Q2 24
24.9%
Q1 24
Capex Intensity
CORT
CORT
TXO
TXO
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
Q1 24
0.0%
Cash Conversion
CORT
CORT
TXO
TXO
Q4 25
1.58×
Q3 25
2.77×
6.50×
Q2 25
1.25×
Q1 25
0.25×
12.67×
Q4 24
1.93×
3.96×
Q3 24
1.56×
102.02×
Q2 24
1.16×
8.15×
Q1 24
0.86×
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

TXO
TXO

Oil And Condensate$92.8M89%
Natural Gas Liquids Reserves$8.2M8%
Other$2.8M3%

Related Comparisons